

Date: 16 March 2022

**Re: Freedom of Information Request**

**Ref: 81-2022**

Thank you for your email dated the 14/3/2022, requesting information in relation to prostate cancer treatment.

The information that you require is as follows:

- 1. Please provide the total number of patients treated in the last 3 months (Dec 21 - Feb 22) with any systemic anti-cancer treatment for:**

	Number of patients
Prostate cancer (any stage)	908
Metastatic prostate cancer	395

- 2. How many patients were treated for prostate cancer (any stage) in the past 3 months (Dec 21 - Feb 22) with:**

	Number of patients
• Androgen Deprivation Therapy (ADT) standalone	below
• Abirateroneacetate	213
• Apalutamide	19
• Bicalutamide	22
• Darolutamide	13
• Degarelix	8
• Triptorelin	186
• Abiraterone (Zytiga) in combination with any ADT	3
• Abiraterone (Zytiga) - no ADT	213
• Enzalutamide (Xtandi) in combination with any ADT	0
• Enzalutamide (Xtandi) - no ADT	380
• Apalutamide (Erleada) in combination with any ADT	0
• Darolutamide (Nubeqa) in combination with any ADT	0
• Cabazitaxel (Jevtana)	17
• Docetaxel in combination with any ADT	0

•	Docetaxel – no ADT	51
•	Degarelix (Firmagon)	8
•	C (Lynparza)	0

**3. How many metastatic prostate cancer patients were treated in the past 3 months (Dec 21 - Feb 22) with:**

		Number of patients
•	Androgen Deprivation Therapy (ADT) standalone	below
	Apalutamide	12
	Bicalutamide	2
	Darolutamide	3
	Degarelix	5
	Enzalutamide	226
	Triptorelin	32
•	Apalutamide (Erleada) in combination with any ADT	0
•	Apalutamide in combination with any ADT	0
•	Docetaxel – no ADT	21

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

**In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:**

<https://www.surveymonkey.co.uk/r/H39RFMM>

Kind Regards,

Margaret Moore  
Information Governance Administrator  
Contact Email: [ccf-tr.foi@nhs.net](mailto:ccf-tr.foi@nhs.net)